Neonc Technologies Holdings (NTHI) Income from Continuing Operations (2024 - 2026)
Neonc Technologies Holdings (NTHI) posted quarterly Income from Continuing Operations of 7985967.0 for Q1 2026, up 75.17% year-over-year from 4559071.59 in Q1 2025, and up 46.67% quarter-over-quarter from 14973797.0 in Q4 2025.
Neonc Technologies Holdings (NTHI) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Neonc Technologies Holdings (NTHI) has reported Income from Continuing Operations for 3 consecutive years, with 7985967.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 75.17% year-over-year to 7985967.0; the TTM figure through Mar 2026 stood at 36527648.0 (up 0.83% YoY), while the FY2025 annual figure was 82201403.0, down 347.39% from the prior year.
- Income from Continuing Operations climbed to 7985967.0 in Q1 2026 per NTHI's latest filing, from 14973797.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 382160.0 in Q2 2024 and bottomed at 32158065.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 8477692.67 across 3 years, with a median of 5770237.0 in 2025.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations tumbled 1409.9% — and 2026, when it soared 75.17%.
- Neonc Technologies Holdings' Income from Continuing Operations stood at 2107885.0 in 2024, then sank by 610.37% to 14973797.0 in 2025, then surged by 46.67% to 7985967.0 in 2026.
- Business Quant data shows NTHI's Income from Continuing Operations at 7985967.0 in Q1 2026, 14973797.0 in Q4 2025, and 7797647.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Neonc Technologies Holdings | 116.41 Mn | 116.41 Mn | - | -13.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.94 Mn |
| Mar 31, 2026 | -7.99 Mn |
| Dec 31, 2025 | -14.97 Mn |
| Sep 30, 2025 | -7.80 Mn |
| Jun 30, 2025 | -5.77 Mn |
| Mar 31, 2025 | -32.16 Mn |
| Dec 31, 2024 | -2.11 Mn |
| Sep 30, 2024 | -2.18 Mn |
| Jun 30, 2024 | -382,160.00 |
| Mar 31, 2024 | -2.94 Mn |